{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:54:16Z","timestamp":1790888056208,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the real-world comparative effectiveness of androgen receptor pathway inhibitors (ARPIs)\u2014abiraterone, apalutamide, enzalutamide\u2014and docetaxel, plus androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified US men with mHSPC who initiated ADT within 4 months of diagnosis and were treated with abiraterone, apalutamide, enzalutamide, or docetaxel within 4 months of ADT initiation between January 2019 and December 2023, with follow-up through June 2025. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included time to metastatic castration-resistant prostate cancer (mCRPC) progression (TTP) and time to new treatment initiation (TTNT). Cox proportional hazard and Fine-Gray models with overlapping propensity score weights were used to estimate primary and secondary outcomes, respectively. Subgroup analyses by timing of metastasis and sensitivity analyses using inverse probability of treatment weights were conducted for primary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 9,141 US men with mHSPC, ARPI doublets demonstrated superior PFS versus docetaxel doublets (abiraterone: adjusted hazard ratio [aHR], 0.60 [95% CI, 0.55 to 0.66]; apalutamide: aHR, 0.64 [95% CI, 0.56 to 0.73]; enzalutamide: aHR, 0.57 [95% CI, 0.51 to 0.64]), with no significant differences among ARPI regimens. OS was comparable among all doublet regimens. Neither PFS nor OS differed by timing of disease. TTP (abiraterone: aHR, 0.52 [95% CI, 0.47 to 0.58]; apalutamide: aHR, 0.59 [95% CI, 0.52 to 0.68]; enzalutamide: aHR, 0.51 [95% CI, 0.45 to 0.57]) and TTNT (abiraterone: aHR, 0.46 [95% CI, 0.42 to 0.51]; apalutamide: aHR, 0.53 [95% CI, 0.46 to 0.61]; enzalutamide: aHR, 0.47 [95% CI, 0.42 to 0.53]) showed similar patterns favoring ARPI doublets. Sensitivity analyses showed consistent findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ARPI doublets demonstrated superior PFS but similar OS compared with docetaxel doublet, with no differences among individual ARPIs. Patients receiving ARPI doublets were less likely to progress to mCRPC or initiate new treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-26-00493","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:59:11Z","timestamp":1790884751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-9327","authenticated-orcid":true,"given":"Ifechukwu B.","family":"Nwogu","sequence":"first","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Kreif","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-8028","authenticated-orcid":true,"given":"Hiba M.","family":"Khan","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA"},{"name":"Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-6370","authenticated-orcid":true,"given":"Ruth","family":"Etzioni","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutch Cancer Center, Seattle, WA"},{"name":"Department of Biostatistics, University of Washington School of Public Health, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-8370","authenticated-orcid":true,"given":"Josh J.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz396"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01798"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01920-4"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24813"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40730"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.9433"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.003"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.013"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03207-6"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0023"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1879753"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00690"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad046"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4372"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5753"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1214\/19-AOAS1282"},{"key":"e_1_3_7_28_2","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li F","year":"2019","unstructured":"Li F, Thomas LE, Li F: Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188:250-257, 2019","journal-title":"Am J Epidemiol"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7819"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jahd.2024.100014"},{"key":"e_1_3_7_31_2","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna Austria: R Foundation for Statistical Computing 2024. https:\/\/www.R-project.org\/"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00648"},{"key":"e_1_3_7_33_2","volume-title":"forestplot: Advanced Forest Plot Using \u201cgrid\u201d Graphics","author":"Gordon M","unstructured":"Gordon M, Lumley T: forestplot: Advanced Forest Plot Using \u201cgrid\u201d Graphics. https:\/\/cran.r-project.org\/web\/packages\/forestplot\/index.html"},{"key":"e_1_3_7_34_2","unstructured":"Therneau T: A Package for Survival Analysis in R"},{"key":"e_1_3_7_35_2","volume-title":"survminer: Drawing Survival Curves Using \u201cggplot2.\u201d CRAN: Contributed Packages","author":"Kassambara A","year":"2016","unstructured":"Kassambara A, Kosinski M, Biecek P: survminer: Drawing Survival Curves Using \u201cggplot2.\u201d CRAN: Contributed Packages, 2016. 2016:0.5.1"},{"key":"e_1_3_7_36_2","volume-title":"survey: Analysis of Complex Survey Samples","author":"Lumley T","year":"2025","unstructured":"Lumley T, Gao P, Schneider B, et al: survey: Analysis of Complex Survey Samples. 2025. https:\/\/cran.r-project.org\/web\/packages\/survey\/index.html"},{"key":"e_1_3_7_37_2","volume-title":"Tableone: Create \u201cTable 1\u201d to Describe Baseline Characteristics with or Without Propensity Score Weights","author":"Yoshida K","year":"2022","unstructured":"Yoshida K, Bartel A, Chipman JJ, et al: Tableone: Create \u201cTable 1\u201d to Describe Baseline Characteristics with or Without Propensity Score Weights. 2022. https:\/\/cran.r-project.org\/web\/packages\/tableone\/index.html"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686"},{"key":"e_1_3_7_39_2","volume-title":"WeightIt: Weighting for Covariate Balance in Observational Studies","author":"Greifer N","year":"2025","unstructured":"Greifer N: WeightIt: Weighting for Covariate Balance in Observational Studies. 2025. https:\/\/cran.r-project.org\/web\/packages\/WeightIt\/index.html"},{"key":"e_1_3_7_40_2","volume-title":"HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors","author":"CMS","unstructured":"CMS: HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors. https:\/\/www.cms.gov\/newsroom\/press-releases\/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower"},{"key":"e_1_3_7_41_2","volume-title":"Selected Drugs and Negotiated Prices","author":"CMS","unstructured":"CMS: Selected Drugs and Negotiated Prices. https:\/\/www.cms.gov\/priorities\/medicare-prescription-drug-affordability\/overview\/medicare-drug-price-negotiation-program\/selected-drugs-negotiated-prices"},{"key":"e_1_3_7_42_2","volume-title":"Real-World Evidence","author":"Commissioner O of the","year":"2024","unstructured":"Commissioner O of the: Real-World Evidence. FDA, 2024. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05388-1"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4184"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20250313"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7762"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1148021"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2241985"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00929-6"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280220940334"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4221"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:59:13Z","timestamp":1790884753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":51,"alternative-id":["10.1200\/OP-26-00493"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00493","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00493"}}